Analyst Josh Jennings from TD Cowen maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at $324.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Josh Jennings has given his Buy rating due to a combination of factors, including the strategic appointment of Ashley McEvoy as the new CEO of Insulet. McEvoy’s extensive experience in the medical device industry, particularly her leadership role at JNJ MedTech, is expected to bring valuable insights and stability to the company, reassuring investors amidst the unexpected CEO transition.
Furthermore, Insulet’s announcement of anticipated revenue performance exceeding its first-quarter guidance and plans to raise future guidance highlights the company’s strong operational footing. These positive financial indicators, coupled with the leadership change, contribute to Jennings’s confidence in the company’s growth potential, justifying the Buy rating.